Latest news, reports, and more from the RedChip Nation.
Discovering Tomorrow's Blue Chips Today
January 07, 2020     Contact    
Can-Fite BioPharma (NYSE American: CANF) Issues Letter to Shareholders


Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, issued a letter to shareholders from its CEO, Dr. Pnina Fishman.


Key Highlights:

  • Namodenoson NASH top line results expected Q1 2020
  • Namodenoson Phase III study design for liver cancer receives FDA’s agreement
  • Namodenoson is approved for use in Israel under Compassionate Use Program
  • Namodenoson has potential utilization as anti-obesity drug based on new data
  • Piclidenoson progresses in Phase III studies
  • Out-licensing drugs for non-dilutive funding
  • Additional value creating opportunities with strategic partners


Key Quote: “We made significant progress in our drug development programs during 2019 and are entering 2020 with the expectation of major value-driving events over the next 12 months." – Dr. Pnina Fishman, CEO


The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.



Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.

SinglePoint’s (OTCQB: SING) Direct Solar Subsidiary Sponsors Real Run Winter Classic 2020


Direct Solar of America, a subsidiary of SinglePoint (OTCQB: SING), sponsored the Real Run Winter Classic 2020 in Torrance, California on January 3rd and 4th.


Why It Matters: The main games of the Winter Classic aired on ESPN, providing network coverage Direct Solar and other sponsors. Other sponsors included Nike, 7eleven, Uptime Energy Drink, and SchollyMe, a social platform for athletes to showcase their ability and partner of Direct Solar.


Key Quote: “This is a great opportunity for the athletes and those involved with Real Run. It provides a platform for them to showcase their talents and become a part of a community of people trying to better themselves and the community. We are very excited to be involved with Real Run and being able to bring in great partners such as Direct Solar of America to continue growing the platform.” – Melvin Nunnery, Founder of SchollyME


The Backstory: Founded in 2011, SinglePoint invests in and acquires brands and companies that will benefit from injection of growth capital and the sales and marketing expertise of SinglePoint. The company's portfolio currently includes solar renewables, Hemp and distribution tobacco products. SinglePoint is working to grow the company to a multi-national brand.



SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.

Quote of the Week
"The single most important way we attempt to manage risk, in any environment, is by seeking to buy stocks very cheaply-we never want to pay too much."
- Bill Hench, Portfolio Manager, Royce Opportunity Funds
Lesson of the Week
The importance of leadership.
Read More
Latest Videos
Dividend Paying REIT with $4.75 Price Target from Aegis
Medalist Diversified REIT (NASDAQ: MDRR) is a public Virginia-based Real Estate Investment Trust specializing in acquiring, owning and managing value-add commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns.
Watch Now
Boxlight CEO Interview: Double-Digit Growth for Leading Interactive Tech Provider
Boxlight (Nasdaq: BOXL) is a leading provider of technology solutions for the global education market. The company aims to improve learning and engagement in classrooms and to help educators enhance student outcomes, by developing the products they need. The company develops, sells, and services its integrated, interactive solution suite including software, classroom technologies, professional development and support services.
Watch Now
Can-Fite CEO Interview: Multiple Phase III Clinical Trial Programs
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH.
Watch Now
Immuron's New Antibiotic Alternative Generating Strong Sales Growth
Immuron Ltd. (NASDAQ: IMRN; ASX: IMC), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Watch Now
Interview with Leading Tech Developer for Maritime Industry
eMARINE Global (OTC: EMRN) is a leading provider of information and communications technology (ICT) solutions for the global maritime industry.
Watch Now
Preferred Shares Pay Quarterly Distributions at 12% Per Annum Rate
1847 Holdings (OTC: EFSH) seeks to provide non-correlated returns by combining the most attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly-traded company. 1847’s unique structure permits flow-through tax treatment for shareholders. As a result, 1847 will seek to generate returns for shareholders through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.
Watch Now
Can-Fite BioPharma Webinar
Watch our exclusive investor webinar with Can-Fite BioPharma Ltd. (NYSE American: CANF) CEO Dr. Pnina Fishman to learn why the stock has been attracting positive attention this year and what the upside potential is from here.
Watch Now
SinglePoint: Diversified Operations Driving Rapid Revenue Growth
SinglePoint (OTCQB: SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services, solar, and blockchain solutions.
Watch Now
Genetic Technologies: New Risk Assessment Tests for Cancer
Exclusive interview with Dr. Jerzy Mechnicki , interim-CEO of Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.
Watch Now
Order Small Stocks, Big Money Today!
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
MidSouth Week in Review
The 10-year Treasury closed out 2019 with a yield of 1.9%, its lowest year-end close in seven years.
Read More
Weekly Index Performance
Indexes were mixed during the shortened holiday trading week.
Read More
About RedChip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and view RedChip’s Disclosures.
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.